Wave Life Sciences

Yahoo Finance • 4 days ago

Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks

The stock market has been treading water so far this year, with the S&P 500 up roughly 1% while the Nasdaq has slipped 1.5%. Tech stocks have struggled to regain last year’s momentum as investors reassess the durability of AI-driven spendi... Full story

Yahoo Finance • 8 days ago

BofA Highlights WVE-007 as Primary Driver For Wave Life Sciences Ltd. (WVE)’s Growth, Projecting Peak Sales Above $11B

Wave Life Sciences Ltd. (NASDAQ:WVE) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.BofA Highlights WVE-007 as Primary Driver For Wave Life Sciences Ltd. (WVE)'s Growth, Projecting Peak Sales Above $11B Wave Lif... Full story

Yahoo Finance • 10 days ago

Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program

Wave Life Sciences (NASDAQ:WVE) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 closing, consensus sentiment around Wave Life Sciences (NASDAQ:WVE) remained strongly bullish. The stock received cover... Full story

Yahoo Finance • 21 days ago

Microsoft downgraded, Snap upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: B. Riley upgraded Snap (SNAP) to Buy fro... Full story

Yahoo Finance • 23 days ago

Wave Life Sciences price target raised to $50 from $47 at Clear Street

Clear Street raised the firm’s price target on Wave Life Sciences (WVE) to $50 from $47 and keeps a Buy rating on the shares after GSK (GSK) returned the rights to WVE-006 for alpha1-antitrypsin deficiency. The firm views the news as an “o... Full story

Yahoo Finance • 24 days ago

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver ma... Full story

Yahoo Finance • 2 months ago

Oppenheimer and Truist Lift Wave Life Sciences Ltd. (WVE) Price Targets After Positive Trial

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Wave Life Sciences Ltd. tops our list for being one of the most promising stocks. TheFly reported on December 16 that Oppenheimer raised its pr... Full story

Yahoo Finance • 2 months ago

Wave Life (WVE) Shares Nearly Triple on Encouraging Obesity Drug Trial

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the last week’s heavy gainers. Wave Life Sciences nearly tripled its share price on a week-on-week basis, as investors posi... Full story

Yahoo Finance • 3 months ago

Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss

Eli Lilly is putting the "obesity field on notice again," an analyst said Thursday after its next-gen delivered 28.7% weight loss. Continue Reading... Full story

Yahoo Finance • 3 months ago

Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7%

Eli Lily rose above a key level after saying its experimental obesity treatment delivered 23.7% weight loss in a late-stage trial. Continue Reading... Full story

Yahoo Finance • 3 months ago

Wave Life Science prices upsized $350M stock ofeering

* Wave Life Sciences (WVE [https://seekingalpha.com/symbol/WVE]) priced [https://seekingalpha.com/pr/20334510-wave-life-sciences-prices-upsized-350-million-public-offering-of-ordinary-shares-and-pre] an upsized underwritten public offeri... Full story

Yahoo Finance • 3 months ago

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life S... Full story

Yahoo Finance • 3 months ago

Trending tickers: Nvidia, Wave Life, Toll Brothers, British American Tobacco and Moonpig

Nvidia (NVDA) US president Donald Trump announced on Monday that he will allow the sale of Nvidia's (NVDA) more powerful H200 chips to China. Trump wrote in a post on Truth Social on Monday that he had informed China's president Xi Jinpi... Full story

Yahoo Finance • 3 months ago

After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance

(RTTNews) - Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance. Exicure, Inc... Full story

Yahoo Finance • 3 months ago

Biggest Stock Movers Today, Dec. 8: CFLT, UL, & More

Key Points Major stock market indexes were mixed on Thursday. Some AI stocks rose while others fell as earnings results kept coming out.10 stocks we like better than Confluent › Investors came into the new week on Monday largely in wait-... Full story

Yahoo Finance • 3 months ago

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life S... Full story

Yahoo Finance • 3 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Paranovus Entertain.Tech. Ltd. 852,838,067 0.0658 0.0476 0.05 +0.0134 Co... Full story

Yahoo Finance • 3 months ago

Turnarounds and 18,000% Growth

DENVER, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Markets opened the week with a burst of small-cap energy as several niche innovators, spanning luxury foods, next-gen biomaterials, and RNA therapeutics, delivered updates that injected fresh opt... Full story

Yahoo Finance • 3 months ago

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07),... Full story

Yahoo Finance • 3 months ago

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim... Full story